The AstraZeneca share price steadies: is this FTSE 100 stock a good investment?

The AstraZeneca share price is showing resilience in the face of disappointing vaccine publicity. This FTSE 100 stock has a lot to like.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 pharmaceutical giant AstraZeneca (LSE:AZN) is showing resilience in the face of vaccine pushback. The company is behind one of the main vaccine rollouts, but 13 European countries have suspended the vaccine on concern it causes blood clots. However, the World Health Organisation (WHO) says there’s no evidence that the vaccine has any link to the clots. AstraZeneca’s share price seems to be holding steady despite the reports.

While the bad press is disappointing for the company, it has plenty of other projects in the pipeline to keep investors interested. Another Covid-19 therapy of note is its antibody treatment designed to boost the immune system of those unable to take the vaccine. The company has sold around $726m worth of this treatment to the US government year-to-date and analysts forecast it could bring in $3bn worth of revenue this year.

AstraZeneca share price fluctuations

The AstraZeneca share price has endured a rather disappointing eight months after the excitement of its vaccine potential sent it rocketing above £93 a share back in July. Today it’s hovering around £72.

For the last 12 months, its price-to-earnings ratio (P/E) is still high at 40. But its forward P/E is a more reasonable 19 and earnings per share are £1.75. It offers shareholders a 2.8% dividend yield.

Acquisitions extend its reach

The company has also been making moves in cancer treatments and rare diseases. Late last year it announced a major acquisition of US biotech company Alexion Pharmaceuticals for $39bn. The AstraZeneca share price took a hit on the news because Alexion was reportedly worth around $26bn. This meant investors thought AstraZeneca had overpaid.

However, many are starting to see the future benefits in owning Alexion, the purchase of which is set to complete in Q3. It should give AstraZeneca a much stronger presence in battling rare diseases. It should also help boost its offering of immunology drugs.

Alexion had a remarkable 2019, achieving six regulatory approvals, seven business development deals, and hiring 800 new employees. Its focus is on researching and treating rare and devastating diseases. This acquisition is not just strengthening AstraZeneca’s business, but it should help improve cash flow, allowing more money to be allocated to research and development (R&D). Analysts believe it may also lead to a stronger dividend payment.

In its bid to streamline the business, AstraZeneca also recently sold its stake in Moderna for over $1bn. This will help towards the Alexion acquisition.

Risks to the business

However, there are always risks worth being aware of and acquisitions can come with their own set of challenges. Legal risks abound, particularly when dealing with healthcare. Then there’s the fact AstraZeneca is paying over the odds. Will it generate enough cash and business opportunities to prove its worth? 

There’s also the risk of reputational damage if the vaccine (or other drug) doesn’t work out as planned. That’s the nature of pharmaceuticals and always a risk investors face.

With the impact of the Covid-19 pandemic not yet resolved, I believe much more focus and government money is likely to be willingly spent on healthcare R&D in the future. I like AstraZeneca and would happily add its shares to my long-term investment portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended Moderna Inc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »